Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Enviro Therapeutics, Inc.
Los Angeles/Southern CA area, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Enviro Therapeutics developed immune-based therapeutics targeting resistance and immune suppression in oncology. Its lead asset, ENV105/Carotuximab, is in Phase II trials for prostate cancer and Phase I for non-small cell lung cancer. Early data suggest promising response rates in heavily pretreated prostate cancer patients. The broader portfolio includes seven drug candidates at various stages.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodiesSmall moleculesAutologous T cell therapy
- Industry
- Biotech
02
Partnerships
Cedars-Sinai Medical Center (technology licensing partner)
Beyond the preview
Go deeper on Enviro Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Enviro Therapeutics, Inc..